Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733904

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733904

Gastric Cancer Diagnostics

PUBLISHED:
PAGES: 372 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Gastric Cancer Diagnostics Market to Reach US$3.0 Billion by 2030

The global market for Gastric Cancer Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$664.5 Million While China is Forecast to Grow at 6.3% CAGR

The Gastric Cancer Diagnostics market in the U.S. is estimated at US$664.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gastric Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Are Advances in Gastric Cancer Diagnostics Crucial for Early Detection and Better Prognosis?

The early detection of gastric cancer is a major challenge, as symptoms often do not appear until the disease has progressed to later stages, leading to poor prognosis and low survival rates. However, advancements in gastric cancer diagnostics are changing the landscape, making it possible to detect the disease at earlier, more treatable stages. As a result, there has been a growing emphasis on developing diagnostic technologies that can identify gastric cancer before it reaches advanced stages. The evolution of imaging techniques, such as endoscopic ultrasound (EUS) and positron emission tomography (PET), has greatly improved the ability to detect gastric tumors and assess their spread. Moreover, biomarker testing is becoming increasingly prominent in the diagnostic process. Researchers have identified a range of biomarkers associated with gastric cancer, including HER2, p53, and CA 19-9, which are helping clinicians to detect the disease more accurately and to personalize treatment plans based on molecular profiles. Liquid biopsy, a non-invasive testing method that analyzes tumor DNA from blood samples, is another breakthrough that is advancing diagnostic capabilities. This approach enables early-stage detection and monitoring of treatment response without the need for invasive procedures. These innovations are crucial as they not only improve the chances of early detection but also offer better chances for curative treatment, significantly enhancing patient outcomes and survival rates. With growing recognition of the importance of early-stage diagnostics, there has been increased investment in research and development, further driving innovation in gastric cancer detection.

How Are Technological Innovations Transforming Gastric Cancer Diagnostics?

Technological innovations are playing a pivotal role in transforming gastric cancer diagnostics, making them more efficient, accurate, and accessible. One of the most significant developments has been the advancement in imaging technologies. Endoscopy, combined with high-definition cameras and advanced imaging techniques like narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), has improved the ability to visualize gastric tumors and precancerous lesions at the cellular level. These technologies allow for earlier detection of abnormal growths and enable more precise biopsies, improving the accuracy of diagnostic results. Furthermore, the advent of artificial intelligence (AI) and machine learning (ML) has significantly enhanced the analysis of diagnostic imaging, enabling more rapid and accurate identification of gastric cancer. AI algorithms can now be trained to detect subtle patterns in imaging data that may be missed by human eyes, helping radiologists and pathologists make faster and more accurate diagnoses. Molecular diagnostics are also seeing rapid growth, with advances in next-generation sequencing (NGS) technology allowing for comprehensive genetic profiling of gastric cancer. This approach provides valuable insights into tumor mutations and gene expression, which can guide targeted therapy and improve patient outcomes. Additionally, liquid biopsy technology, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is revolutionizing non-invasive diagnostics. This method offers a simpler, less invasive alternative to traditional biopsy procedures and holds promise for detecting gastric cancer in its earliest, most treatable stages. These technological breakthroughs are not only improving the speed and accuracy of gastric cancer diagnosis but are also laying the groundwork for more personalized treatment options.

What Are the Key Factors Driving the Demand for Gastric Cancer Diagnostic Solutions?

The growing demand for gastric cancer diagnostic solutions is driven by several factors, including the rising global incidence of gastric cancer, advancements in healthcare infrastructure, and the increasing focus on early detection and personalized medicine. The incidence of gastric cancer is expected to rise in many regions, particularly in East Asia, Central Europe, and parts of Latin America, due to factors such as diet, Helicobacter pylori infection, and genetic predisposition. As the global healthcare system recognizes the importance of early cancer detection, the demand for more advanced diagnostic technologies is increasing. Moreover, the increasing adoption of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsy and endoscopic screening, is making gastric cancer detection more accessible and cost-effective for patients and healthcare providers alike. Governments and health organizations worldwide are also pushing for improved cancer screening programs, especially in high-risk populations, which is further fueling demand for gastric cancer diagnostics. The growth of healthcare infrastructure in emerging markets is another key factor. As developing regions gain access to advanced diagnostic tools, there is a greater focus on cancer prevention, early detection, and treatment. Personalized medicine is another driver of the market, as genetic testing and molecular profiling of tumors are becoming more common to identify the most effective treatment strategies for each patient. Furthermore, as public awareness of gastric cancer increases, there is greater demand for diagnostics that can detect the disease in its early stages before it spreads, which ultimately leads to better outcomes. All these factors combined are driving the increasing demand for gastric cancer diagnostic solutions.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Diagnostics Market?

The growth of the gastric cancer diagnostics market is driven by a combination of factors related to medical advancements, increasing global healthcare investment, and rising awareness of the disease. As the prevalence of gastric cancer continues to rise, particularly in high-risk regions, there is an increased focus on early detection methods that can significantly improve prognosis. Early detection remains one of the most important factors in improving survival rates, which has led to a surge in demand for advanced diagnostic solutions that can identify the disease before it progresses to later, harder-to-treat stages. The rapid development of molecular and genetic diagnostics is another key driver, as researchers and clinicians now have the tools to more accurately profile tumors and tailor treatments to individual patients. The introduction of liquid biopsy as a non-invasive diagnostic tool is further transforming the landscape by offering a method for detecting gastric cancer earlier and more safely than traditional biopsies. Additionally, advancements in imaging technology, including AI-powered imaging systems and high-definition endoscopy, are providing more accurate and detailed assessments of gastric tissue, allowing for improved detection of abnormal growths and early-stage tumors. Furthermore, as healthcare systems across the globe continue to modernize, especially in emerging markets, access to these cutting-edge diagnostic tools is becoming more widespread. The increased recognition of the importance of gastric cancer screening, particularly in high-risk populations, has driven both public and private investments in diagnostic technologies. In addition to technological developments, the growing focus on personalized treatment plans that leverage genetic and molecular data has spurred the demand for diagnostics that can provide more precise and tailored treatment options. With these factors driving innovation and adoption, the gastric cancer diagnostics market is poised for continued growth, offering the potential for better outcomes and survival rates for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Consumables, Instruments); Disease Type (Adenocarcinoma, Gastric Lymphoma, Other Disease Types); End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BD (Becton, Dickinson and Company)
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Biohit Oyj
  • CD Genomics
  • DiaSorin S.p.A.
  • Exalenz Bioscience Ltd.
  • FUJIFILM Holdings Corporation
  • GeneMatrix Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Labcorp Oncology
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33882

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Gastric Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Gastric Cancer Worldwide Drives Increased Demand for Advanced Diagnostic Solutions
    • Growing Awareness of Genetic and Lifestyle Factors Fuels Demand for Comprehensive Gastric Cancer Screening
    • Surge in Investment in Non-Invasive Diagnostic Technologies Expands Market Opportunities for Gastric Cancer Detection
    • Advancements in Liquid Biopsy and Molecular Diagnostics Drive Accuracy and Sensitivity in Early Diagnosis
    • Here's How the Integration of AI and Machine Learning in Diagnostic Tools is Enhancing Gastric Cancer Detection
    • Increased Adoption of Endoscopic Screening Methods Boosts Early Detection Rates and Market Growth
    • Growing Role of Biomarkers in Gastric Cancer Diagnostics Strengthens the Business Case for Precision Medicine
    • Rising Demand for Point-of-Care Diagnostics Expands Access to Early Gastric Cancer Detection in Remote Areas
    • Technological Innovations in Imaging and Optical Methods Enhance Diagnostic Precision and Minimize Invasiveness
    • Rising Focus on Multi-Omic Approaches, Including Genomic and Proteomic Profiling, Drives Diagnostic Advancements
    • Expanding Use of Companion Diagnostics for Personalized Treatment Planning in Gastric Cancer Strengthens Market Potential
    • Rising Focus on Early Detection in High-Risk Populations Creates Opportunities for Targeted Screening Solutions
    • Increased Demand for Integrated Healthcare Solutions and Data Analytics Platforms Enhances Gastric Cancer Diagnostic Accuracy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gastric Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gastric Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diagnostic Imaging Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • INDIA
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
  • AFRICA
    • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!